%0 Journal Article
%T Efficacy of CapeOX plus Cetuximab Treatment as a First-Line Therapy for Patients with Extended RAS/BRAF/PIK3CA Wild-Type Advanced or Metastatic Colorectal Cancer
%A Hideyuki Mishima
%A Hiroaki Nagano
%A Hiromichi Maeda
%A Junichi Sakamoto
%A Koji Oba
%A Naoki Nagata
%A Naoko Okayama
%A Nobuaki Suzuki
%A Shigeyoshi Iwamoto
%A Shoichi Hazama
%A Takahiro Yamasaki
%A Yutaka Suehiro
%J Journal of Cancer
%D 2018
%I Ivyspring International Publisher
%R 10.7150/jca.26840
%X Background: Oxaliplatin and capecitabine (CapeOX) combined with cetuximab is rarely used to treat advanced and metastatic colorectal cancer (mCRC). The present study aimed to clarify the clinical benefits of this treatment regimen when used as a first-line therapy in patients with expanded RAS/BRAF/PIK3CA wild-type mCRC, using the data and tumor specimens from two previously published Phase II clinical trials.
%K cetuximab
%K BRAF
%K CapeOX
%K XELOX
%K PIK3CA
%U http://www.jcancer.org/v09p4092.htm